Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INHL001
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical Holdings
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
INHL001 is a preclinical small molecule drug candidate developed by Lee's Pharmaceutical for the treatment of respiratory viral infections. It is an inhaled formulation designed to act as an RNA-directed RNA polymerase (RdRp) inhibitor, a mechanism that interferes with the replication of various RNA viruses. The drug is part of Lee's Pharmaceutical's specialized inhalation platform, which focuses on delivering therapeutic agents directly to the respiratory tract via nebulization. While the code INHL001 was historically associated with the company's amikacin inhalation project in earlier pipeline iterations, current company data identifies it as a distinct preclinical antiviral program for respiratory diseases.
Beyond the preview
Go deeper on INHL001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INHL001.